Login to Your Account



$30M Series B Will Fund Aerie's Lead AR-12286

By Tom Wall


Tuesday, March 8, 2011
Aerie Pharmaceuticals Inc. closed a $30 million Series B financing that is expected to fund additional Phase II studies and the start of Phase III trials by the end of 2011 for lead product AR-12286, a selective Rho-kinase inhibitor treatment for glaucoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription